Bridging the Gaps in Lung Cancer: 6 Month Update Winter Lung Cancer Conference 2025 - Episode 9
Expert Insights for Treatment Sequencing in EGFR-Mutant Advanced NSCLC in the Second Line and Beyond
Panelists discuss how MARIPOSA-2 (Popat S, et al, ESMO 2024) and the September 2024 FDA approval of amivantamab plus chemo as a second-line option highlight advances in non–small cell lung cancer (NSCLC) treatment. Strategies involve sequencing with emerging therapies like HERTHENA-Lung01, addressing resistance, and central nervous system (CNS) metastases. The complete response letter (CRL) for HER3-DXd and the shift in biologics license application (BLA) status for Dato-DXd from TROPION-Lung05 (Lisberg A, et al, ASCO 2024) will shape clinical practices and resistance management moving forward.
Video Player is loading.
Video content above is prompted by the following:
- Briefly comment on MARIPOSA-2 (Popat S, et al. ESMO 2024. Abs LBA54)and the recent FDA approval (September 2024) of combination amivantamab plus chemo as a second-line treatment option.
- How are you integrating the MARIPOSA-2 regimen into your clinical practice, and how do you sequence it with other available therapies?
- If you use MARIPOSA up front, what is your strategy in the second-line setting?
- How do emerging data from the HERTHENA-Lung01 study (Johnson M, et al. ESMO 2023. Abs 1319MO) inform your approach to managing treatment resistance management and CNS metastases?
- How might the recent CRL for HER3-DXd impact clinical practice over the next year?
- What are your perceptions of the latest data from TROPION-Lung05 and the recent shift in BLA status for Dato-DXd?(Lisberg A, et al. ASCO 2024. Abs 8593)
